DRD1: A Drug Target / Disease Biomarker (G1812)

Target Name: DRD1

NCBI ID: G1812

DRD1

DRD1: A Drug Target / Disease Biomarker

DRD1, short for dopamine receptor D1, is a protein that is expressed in the brain and plays a crucial role in the function of dopamine, a neurotransmitter that is responsible for many important cognitive and behavioral processes in the brain. DRD1 has been identified as a potential drug target for the treatment of various neurological disorders, including Parkinson's disease, addiction, and schizophrenia.

DRD1 is a transmembrane protein that is composed of an extracellular region, a transmembrane region, and an intracellular region. The extracellular region consists of a N-terminus that is involved in cell adhesion and interaction, a C-terminus that is involved in protein-protein interactions, and a variable region that contains the catalytic active site and the D2-D3 domains that are involved in the binding of dopamine. The transmembrane region consists of a highly conserved carboxy-terminal region and a hydrophobic region that is involved in the regulation of the activity of the protein. The intracellular region consists of a cytoplasmic region that is involved in the regulation of the stability and localization of the protein and a nuclear localization region that is involved in the interaction with DNA and other cellular structures.

DRD1 is a key protein that is involved in the regulation of dopamine release and uptake in the brain. It is expressed in the midbrain, which is the region of the brain that is responsible for many important cognitive and behavioral processes, including motivation, pleasure, and movement. DRD1 is also expressed in other regions of the brain, including the prefrontal cortex, basal ganglia, and cerebellum, and is involved in the regulation of dopamine release and uptake in these regions.

DRD1 has been identified as a potential drug target for the treatment of various neurological disorders due to its involvement in the regulation of dopamine function. One of the main reasons for this is the fact that DRD1 is involved in the regulation of dopamine release and uptake, which is a critical step in the development and progression of many neurological disorders. For example, DRD1 has been identified as a potential drug target for the treatment of Parkinson's disease, which is a neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain.

DRD1 has also been identified as a potential drug target for the treatment of addiction, which is a complex neuropsychiatric disorder that is characterized by the compulsive behaviors and cravings that are often associated with substance abuse. Many studies have shown that DRD1 is involved in the regulation of dopamine release and uptake in the brain, and that changes in DRD1 function may play a role in the development and progression of addiction. Therefore, DRD1 has been identified as a potential drug target for the treatment of addiction.

DRD1 has also been identified as a potential drug target for the treatment of schizophrenia, which is a neuropsychiatric disorder that is characterized by the development of hallucinations, delusions, and disorganized thinking. Many studies have shown that DRD1 is involved in the regulation of dopamine release and uptake in the brain, and that changes in DRD1 function may play a role in the development and progression of schizophrenia. Therefore, DRD1 has

Protein Name: Dopamine Receptor D1

Functions: Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

The "DRD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets